Veno-arterial extracorporeal membrane oxygenation (ECMO) is utilised as a short-term mechanical circulatory assist device for treatment of refractory acute cardiogenic shock. After a period of support, called "bridge to decision", the options for ensuing therapy include weaning from ECMO, switch to a long-term ventricular assist device, or heart transplantation, depending on the occurrence of myocardial recovery and the presence of and renal adverse events, as well as from the particular circumstances of cardiogenic shock. The condition triggers a cascade of systemic inflammation, which is aggravated depending on the duration of the hypotensive period. The extent of the subsequent multiorgan dysfunction syndrome substantially affects outcome. As a consequence, early ECMO implantation is advocated. In unclear neurological conditions and severely compromised e nd-organ function, t he a nticipated poor outcome has to be weighed very carefully against ethical and economical aspects before ECMO is initiated.
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with those on ventilator therapy only [1] , the use of ECMO for ARDS has grown tremendously. Also for cardiac failure, usage of vaECMO becomes more and more popular. The technical advancement of ECMO pumps and tubing, as well as the unfavourable results of the SHOCK II trial for the use of the intraaortic ballon pump in cardiogenic shock [2] have led to a broader application of vaECMO. In postcardiotomy syndrome, vaECMO therapy is associated with rather poor results due to the critical myocardial damage during cardiac surgery [3] . The management of ECMO is still challeng- 
The state of cardiogenic shock
Cardiogenic shock is far more than loss of cardiac contractility with subsequent low output syndrome. It is a complex, degenerating clinical downward spiral of multiorgan dysfunction that begins when the heart is no longer able to provide sufficient flow to the peripheral organs [14] . Hypotension, systemic hypoperfusion and end-organ ischaemia follow. Compensatory vasoconstriction is insufficient, at least in part because of
Introduction
Extracorporeal m embrane oxygenation ( ECMO) is established as veno-venous ECMO (vvECMO) for respiratory failure and as veno-arterial ECMO (vaECMO) for cardiogenic shock which may result from acute or acute-on-chronic heart failure and from postcardiotomy syndrome subsequent to cardiac surgery. Therapy with ECMO has been steadily increasing over the past few years. This is mainly due to its application as vvECMO in respiratory failure, particularly acute respiratory distress syndrome (ARDS [15, 19] . The main reason for the failure of NOS inhibition to improve outcome in cardiogenic shock might be t hat a nonselective NOS inhibition was applied, which also inhibited the two other NOS isoforms, endothelial (eNOS) and neuronal (nNOS) and, thereby, adversely affected the protective actions of constitutively generated NO [15] . In septic shock, nonselective NOS inhibition has been shown to even increase m ortality [ 20] . O ther t rials examining the effects of various mediator-specific anti-inflammatory agents in septic shock, directed against TNF-α, IL-1, platelet activating factor, and others, were not able either to demonstrate an improvement in outcome [15, 21] . More general, nonspecific anti-inflammatory treatment of septic s hock w ith low-dose s teroids achieved, in contrast to high dosage, beneficial effects on survival, presumably since low steroid doses still attenuate the deleterious effects of systemic inflammation, while they do not eliminate the favourable actions of low-grade cytokine activation [15, 22] . This concept might be a way to improve outcome also in cardiogenic shock. The restoration of cardiac output via ECMO is intended to reverse this inflammatory cascade.
ECMO treatment strategies
Veno-arterial ECMO for cardiogenic shock is implanted in an emergency situation. There is not much time to make a decision about which therapeutic approach will follow ECMO. Potential comorbidities and the psychosocial environment cannot be evaluated, but this is a precondition before a therapeutic concept can be elab- 
Technical aspects: ECMO mode and configuration
The indication for ECMO determines the ECMO mode and configuration. While in respiratory failure, ECMO is implanted as a veno-venous circuit, cardiogenic shock requires ECMO in a veno-arterial configuration.
For venous drainage, a cannula is inserted into the right atrium through puncture of the common femoral vein (CFV). The right CFV is preferred since advancement of the cannula might be easier on the right side than the left side as a result of the bent course of the 
Outcome

Early survival
The outcome after ECMO therapy for cardiogenic shock is associated with low survival rates. But taking into account that, without ECMO, survival w ould b e extremely poor, the outcome may be r egarded as accept able. Several notable studies reported early survival of approximately 40% (fig. 2) . The group in La Pitié, Paris, which is one of the most experienced centres in ECMO therapy, retrospectively examined 81 patients who were put on ECMO for cardiogenic shock due to medical, postcardiotomy or posttransplantation heart failure [5] . The analysis showed a 42% survival to h ospital discharge and a 38% survival a t survival from refractory cardiogenic shock requiring ECMO [6] . The availability of a reliable score is a serious concern of each centre offering ECMO therapy. Because of the tremendous costs for specialised personnel, ICU may be explained by the fact that 10 of the 20 studies included only patients with cardiogenic shock due to postcardiotomy syndrome, which is known to be associated with poor survival [3] . For all these reasons, the meta-analysis of Xie et al. [7] currently represents the best overview on early outcomes following ECMO for refractory cardiogenic shock, keeping in mind that large randomised studies have not been performed so far and, thus, at the moment pooled analysis represents t he b est available method f or evaluating ECMO [7] .
ELSO = Extracorporeal Life Support Organisation
Long-term results
Long-term results following ECMO for refractory cardiogenic shock are reported scarcely in the literature.
In the meta-analysis by Xie et al. [7] , the estimated 3-year survival was 42.7%, which was rather comparable to the survival to discharge, indicating that mortality was low once patients survived the initial hospitalisation for cardiogenic shock with subsequent ECMO therapy [7] . This has also been described in two other studies by Wu et al. [10] and Lidén et al. [11] . They reported 88% 3-year and 100% 5-year survival, respectively, of those patients who survived until hospital discharge following ECMO f or nonpostcardiotomy cardio genic shock or cardiac arrest [10, 11] . This corresponded with an overall 47% 3-year and a 63% 5-year survival, respectively. The C leveland C linic group reported much lower 3-year and 5-year survival rates of 26% and 24%, respectively [12] . This is explained by the fact that 53% of the 202 patients examined received the ECMO for postcardiotomy cardiogenic shock which is, as mentioned above, associated with poor outcome [3, 12] . Patients who receive the ECMO for cardiogenic shock due to acute myocardial infarction seem to do better than patients in cardiogenic shock because of acute decompensating chronic cardiomyopathy [13] .
Bermudez et al. found in their small cohort of 42 patients that at 2 years after ECMO therapy, 48% of infarct patients w ere alive, as compared with only 11% o f patients with previous chronic heart failure [13] . The poorer outcomes of patients with acutely decompensated chronic heart failure might be explained by the higher frequency of systemic, hepatic and renal involvement at the time of ECMO initiation, indicating the lower reserve of such patients to withstand an acute decompensating event [13] .
Complications
Vascular
Morbidity on ECMO is considerable and frequently has an unfavourable impact on outcome. More than half of all patients develop one or more major ECMO-related complication [5] . of patients [5, 7, 9, 12] . As a consequence, in 2-10% of patients a fasciotomy is needed, and in 2-5% of patients an amputation is performed [7, 9, 12] . To prevent such complications, which may be life-determining, the current state of the art is to place a distal perfusion limb into the SFA at the time of ECMO implantation.
Bleeding
Bleeding complications are triggered by the disseminated intravascular coagulation disorder, which is frequently associated with cardiogenic shock, insufficient production of coagulation factors resulting from liver failure, thrombocytopenia and the need for anticoagulation on ECMO. Major bleeding is reported to occur in 26-41% of patients [5, 7, 9] . Bleeding at the peripheral implantation site is described in 32% of patients [5] .
Neurology
Neurological complications include ischaemic stroke, cerebral bleeding, diffuse anoxic and metabolic brain injury and brain death. They may result from insufficient cerebral perfusion in cardiogenic shock or cardiac arrest before ECMO implantation, or develop under ECMO therapy caused by the complex coagulation disorder following cardiogenic shock. Two large metaanalyses reported the cumulative rate of all neurological complications to be at 13% [7, 9] , another singlecentre study described neurological events in 33% of patients [12] . In particular, ischaemic or haemorrhagic stroke is experienced by 6-8% of patients [7, 9] . high as 47-55% [ 7, 9 ] . Renal replacement therapy is required in 40-46% of all ECMO patients [9, 12, 13] .
Infection
Concluding comment
The fact that cardiogenic shock is not just a compro- interval has been shown to be a risk factor for mortality [5, 11] . This was most clearly shown in the extreme case scenario of the cardiogenic shock spectrum, namely ongoing CPR treated with ECMO (ECPR) [23] . Rapid implantation of ECMO is required to keep the period of low output as short as possible and to break the vicious cycle of inflammation early in its evolution. This, however, implies organisational and structural challenges, including mobile ECMO teams. The significant complication rates of ECMO therapy have to be incorporated into the risk-benefit analysis before treatment is initiat ed [7] . In patients with unclear neurological status, e.g., following unwitnessed out-of-hospital arrest, or with advanced end-organ failure and metabolic derangement, ECMO therapy may be denied since ethical and economical aspects argue against application of ECMO in patients with anticipated poor outcome.
